The Federal Trade Commission (FTC), along with the states of Alaska, Iowa, Nebraska, and Texas, has filed a lawsuit against the World Professional Association for Transgender Health (WPATH)alleging that the organization made deceptive claims about gender-affirming care for minors. This legal action is part of a broader effort by the Trump administration to restrict access to such care.
The lawsuit claims that WPATH not only misled parents and children but also profited from these alleged deceptions. An FTC spokesperson emphasized the importance of informed decision-making, stating, “Parents have a right to make informed decisions about their children’s health. The FTC will not allow parents and children to be deceived by medical organizations and providers who are prioritizing profit over children’s health and safety.”
The Legal Battle and Investigations
This lawsuit follows an FTC investigation into WPATH, which was temporarily blocked by a federal judge in May. WPATH had sued to halt the probe, arguing that the FTC was violating their First Amendment rights. The FTC has also launched investigations into other medical organizations, including the Endocrine Society and the American Academy of Pediatricsboth of which have also taken legal action to block these investigations.
WPATH has been a leading provider of medical standards for gender-affirming care for over 50 years. The association maintains that their standards are based on “established scientific standards, expert consensus, and patient-centered values.” In response to the lawsuit, WPATH issued a statement asserting their position: “WPATH is in a strong position to prove that the FTC is acting out of pure retaliation as part of the federal government’s relentless and targeted campaign to undermine gender-affirming care by attacking the First Amendment rights and the independence of professional medical organizations.”
Allegations and Counterarguments
The FTC’s complaint alleges that WPATH provided recommendations for medical interventions, including drugs and surgery, for children and adolescents who expressed dissatisfaction with or distress about their sex traits. The complaint further alleges that these recommendations misled parents and children about the medical consensus and necessity, as well as the safety and effectiveness, of such services, in violation of the FTC Act.
WPATH’s guidelines, which were updated in 2026, omitted all mention of age limitations for certain procedures. The FTC claims that this decision was not based on medical evidence. Additionally, the complaint alleges that WPATH failed to disclose potential side effects of certain pediatric medical transition services, including mood disturbances, vocal pain, and other health issues.
The lawsuit also highlights instances where parents were asked by clinicians whether they “would rather have a live daughter or a dead son,” based on WPATH representations that pediatric medical transition services are “lifesaving.” The FTC argues that there is no competent and reliable scientific evidence to suggest these interventions reduce the risk of suicide.
Broader Implications
The legal action against WPATH is part of a broader trend where the FTC has launched probes into other medical organizations. The implications for gender-affirming care and the rights of trans individuals are significant. As this legal drama unfolds, the LGBTQ+ community is watching closely to see how the case will impact access to gender-affirming care.
WPATH has vowed to defend itself against these allegations, stating that they are committed to promoting evidence-informed care and guidance for doctors and their patients. The outcome of this lawsuit could set a precedent for future cases involving gender-affirming care and the rights of trans individuals.
